Novartis AG is recognized by external observers as having one of the broadest and richest pipelines in the pharmaceutical industry and while not everything will translate from the clinic to the market, the Basel-headquartered giant is confident that its internal R&D teams will continue to deliver.
Tsai Trumpets Productivity of Novartis Pipeline
Spotlight On Mid-Stage Projects
As the Swiss major took a deep dive on its projects for diseases ranging from pancreatic cancer to osteoarthritis and kidney disease, development head John Tsai spoke about how the firm's digital capabilities are helping those programs advance quicker.
